March 16, 2018
Rohto Pharmaceutical and Japan Tobacco said on March 15 that the partners have entered into a license agreement for the exclusive rights in Japan to develop and commercialize JT’s investigational JAK inhibitor JTE-052 for use in the ophthalmology field. Details...read more